335 related articles for article (PubMed ID: 25814086)
1. The interferon-alpha revival in CML.
Talpaz M; Mercer J; Hehlmann R
Ann Hematol; 2015 Apr; 94 Suppl 2():S195-207. PubMed ID: 25814086
[TBL] [Abstract][Full Text] [Related]
2. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of tyrosine kinase therapy in CML.
Mahon FX
Ann Hematol; 2015 Apr; 94 Suppl 2():S187-93. PubMed ID: 25814085
[TBL] [Abstract][Full Text] [Related]
4. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.
Talpaz M; Hehlmann R; Quintás-Cardama A; Mercer J; Cortes J
Leukemia; 2013 Apr; 27(4):803-12. PubMed ID: 23238589
[TBL] [Abstract][Full Text] [Related]
5. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
[TBL] [Abstract][Full Text] [Related]
6. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
Burchert A; Müller MC; Kostrewa P; Erben P; Bostel T; Liebler S; Hehlmann R; Neubauer A; Hochhaus A
J Clin Oncol; 2010 Mar; 28(8):1429-35. PubMed ID: 20142590
[TBL] [Abstract][Full Text] [Related]
7. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
8. The choice of first-line chronic myelogenous leukemia treatment.
Fava C; Rege-Cambrin G; Saglio G
Ann Hematol; 2015 Apr; 94 Suppl 2(Suppl 2):S123-31. PubMed ID: 25814078
[TBL] [Abstract][Full Text] [Related]
9. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW; Druker BJ
Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
[TBL] [Abstract][Full Text] [Related]
10. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic approaches in chronic myeloid leukemia.
Özgür Yurttaş N; Eşkazan AE
Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
[TBL] [Abstract][Full Text] [Related]
12. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
13. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
14. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Nicolini FE; Hayette S; Legros L; Rousselot P; Maloisel F; Tulliez M; Guerci A; Charbonnier A; Prébet T; Rigal-Huguet F; Chabane K; Magaud JP; Paillet C; Pivot C; Michallet M
Leuk Res; 2011 Jan; 35(1):80-6. PubMed ID: 20605207
[TBL] [Abstract][Full Text] [Related]
15. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
16. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
[TBL] [Abstract][Full Text] [Related]
17. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.
Bremer CT; Lastrapes A; Alper AB; Mudad R
Am J Clin Oncol; 2003 Jun; 26(3):262-4. PubMed ID: 12796597
[TBL] [Abstract][Full Text] [Related]
19. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.
Heibl S; Buxhofer-Ausch V; Schmidt S; Webersinke G; Lion T; Piringer G; Kuehr T; Wolf D; Melchardt T; Greil R; Thaler J
Hematol Oncol; 2020 Dec; 38(5):792-798. PubMed ID: 32757230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]